S&P 500 7,671 -0.27% Nasdaq 26,112 -0.67% Dow Jones 53,484 +0.26% FTSE 100 10,849 +1.13% DAX 26,260 +0.50% Nikkei 225 65,856 +0.81% Hang Seng 25,511 +0.16% WTI Crude 82.47 -6.10% Gold 4,678 +3.58% US 10-Year Treasury Yield 4.66 +0.15% S&P 500 7,671 -0.27% Nasdaq 26,112 -0.67% Dow Jones 53,484 +0.26% FTSE 100 10,849 +1.13% DAX 26,260 +0.50% Nikkei 225 65,856 +0.81% Hang Seng 25,511 +0.16% WTI Crude 82.47 -6.10% Gold 4,678 +3.58% US 10-Year Treasury Yield 4.66 +0.15%

LATEST

Taco Bell is adding enchilada-style loaded fries and energy drinks to its menu●Fromm Family Foods is recalling nearly 5,800 cases of wet dog food over metal fears●Crypto custody firm Copper has potential buyers. But offers are way below its $500 million asking price●Apple is quietly preparing a major change inside its stores●EXCLUSIVE: Watch These 3 AI Bottlenecks Ahead of Nvidia Earnings, Yorkville CEO Says●KKR, GI Partners, O2 Investments target janitorial companies; Windjammer Capital to sell parking biz IPS●Saudi Arabia is funding a $7 billion Dragon Ball Z theme park complex near Paris●These investors own 46% of the entire market value of the NGX●Taco Bell is adding enchilada-style loaded fries and energy drinks to its menu●Fromm Family Foods is recalling nearly 5,800 cases of wet dog food over metal fears●Crypto custody firm Copper has potential buyers. But offers are way below its $500 million asking price●Apple is quietly preparing a major change inside its stores●EXCLUSIVE: Watch These 3 AI Bottlenecks Ahead of Nvidia Earnings, Yorkville CEO Says●KKR, GI Partners, O2 Investments target janitorial companies; Windjammer Capital to sell parking biz IPS●Saudi Arabia is funding a $7 billion Dragon Ball Z theme park complex near Paris●These investors own 46% of the entire market value of the NGX●

Asia

WuXi Biologics posts 4.3% rise in first-half profit, defying biotech headwinds

Business - South China Morning Post · 1h ago · 🇨🇳 China

WuXi Biologics posts 4.3% rise in first-half profit, defying biotech headwinds

WuXi Biologics, one of China’s largest contract drug developers, posted a 4.3 per cent increase in profit attributable to shareholders in the first half of the year, as stronger demand and improved capacity utilisation lifted revenue and margins. The Wuxi, Jiangsu-based company’s net profit attributable to shareholders rose to 2.44 billion yuan (US$363 million) in the six months ended June, according to its filing to the Hong Kong stock exchange on Tuesday. Revenue increased 18.4 per cent to...

Read the full story at Business - South China Morning Post →

More Asia

Scott Bessent’s bond buyback strategy draws criticism from Druckenmiller, JPMorgan: ‘Paying mortgage with credit card’

mint - markets · 43m ago

Euro zone yields dip from multi-year highs as oil falls on Iran sanctions

Markets-Economic Times · 1h ago

Sterling hovers near six-month high underpinned by BoE rate hike expectations

Markets-Economic Times · 1h ago

UK gilt yields fall to lowest since mid-August as oil price slides

Markets-Economic Times · 1h ago